Join Strados at ATS 2025!

Learn More

RESP® for Pulmonary Fibrosis

Monitor the often-overlooked symptom of cough in pulmonary fibrosis patients

Cough is widely rated among the top symptoms by patients that impact their quality of life1. Yet, cough is often overlooked in clinical trials for pulmonary fibrosis, with an unmet need for effective treatments.

While pulmonary function tests remain the primary outcome measure for pulmonary fibrosis treatments, more emphasis from regulators continues to be placed on measuring how patients feel, function and survive5. Cough monitoring has emerged as common practice in clinical trials for IPF treatments to better demonstrate improvement into health-related quality of life.

Additionally, velcro crackles are a common, hallmark symptom in patients with IPF6. While velcro crackles are typically observed for diagnostic purposes in early stages, studies have hinted that crackles might have a relationship to disease severity.7

Cough Monitoring for IPF Studies

The RESP® Biosensor offers sponsors a high-fidelity solution for objectively monitoring cough in a sub-study or as an endpoint for pulmonary fibrosis trials.

  • Clinically validated accuracy, with equivalent performance to Littman 3200 stethoscope.
  • Comprehensive data collected by biosensor allows for greater insights alongside patient-reported outcomes
  • Patient-friendly device that doesn’t interfere with daily life and respects patient privacy.
Certifications: FDA 510(k) clearance, CE Mark, HIPAA Compliant
Strados Cough Monitoring Solution

Actively Seeking Research Collaborations

We’re actively seeking clinical and academic collaborators to expand the evidence base for objective cough and lung sound monitoring. Partners may be eligible for in-kind support.

Learn More

Flexible Reporting—Automated or Human Annotation

Strados RESP biosensor data
  • We offer the gold standard approach for measuring cough – manual cough counting – with our team of respiratory therapists agreeing on hourly counts to meet regulatory and clinical requirements.
  • Machine learning algorithms* have been trained based on validated cough and lung sound events and performance tested to meet customer requirements.
  • Algorithms* allow for compression of cough recordings for manual overread or can be used independently for subject screening and other applications.

**Machine learning algorithms not FDA-cleared

Visual spectrograms of lung sound events facilitate overread for trained specialists

Cough

Wheeze

Crackles

Publications

Explore our peer reviewed performance testing, studies and publications.

Stepwise Validation Program for Cough Detection Algorithm to Monitor Chronic Cough

Objective Cough Monitoring Detects More Patients with Cough Than Patient Self-Reporting
Results of Clinical Performance Testing in Chronic Lung Diseases
View All Publications

What data does the device collect in IPF patients?

The RESP® Biosensor sits on the patient’s chest wall and passively records  patient’s lung sounds including cough, wheeze and crackles. The device also collects motion data to capture respiratory rate*, heart rate*, activity levels*, and body positioning*.

*Measurement not FDA-cleared

How do you know that the RESP® Biosensor is accurate?

The RESP Biosensor has received two FDA 510(k) clearances to record lung sounds. In order to receive FDA clearance,  Strados Labs provided test results that demonstrated audio performance that is substantially equivalent to commercially available electronic stethoscopes.

How is the device adhered to patients’ chests? Does it cause any discomfort?

The non-invasive RESP® Biosensor is placed over the skin and adhered via Tegaderm–acrylic based adhesive. Patients often forget the device is on when wearing and can go on with their daily routines.

Let’s Connect

Explore Using Our Technology in Your Practice or Upcoming Study

Contact Us

References

  1. Lee et al. (2022). Cough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease: Data From the Pulmonary Fibrosis Foundation Patient Registry. Chest, 162(3), 603–613. https://doi.org/10.1016/j.chest.2022.03.025
  2. Cox, I. A., Borchers Arriagada, N., de Graaff, B., Corte, T. J., Glaspole, I., Lartey, S., Walters, E. H., & Palmer, A. J. (2020). Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. European respiratory review : an official journal of the European Respiratory Society, 29(158), 200154. https://doi.org/10.1183/16000617.0154-2020
  3. Wu et al. (2024). Cough Severity Visual Analog Scale Assesses Cough Burden and Predicts Survival in Idiopathic Pulmonary Fibrosis. American journal of respiratory and critical care medicine, 209(9), 1165–1167. https://doi.org/10.1164/rccm.202311-2169LE
  4. Wijsenbeek, et al. (2023). Home monitoring in interstitial lung diseases. The Lancet. Respiratory medicine, 11(1), 97–110. https://doi.org/10.1016/S2213-2600(22)00228-4
  5. Raghu et al. (2024). Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on ‘Feels, Functions, Survives’. American journal of respiratory and critical care medicine. 209. 10.1164/rccm.202312-2213SO; Wijsenbeek, et al. (2023). Home monitoring in interstitial lung diseases. The Lancet. Respiratory medicine, 11(1), 97–110. https://doi.org/10.1016/S2213-2600(22)00228-4
  6. Moran-Mendoza, O., Ritchie, T., & Aldhaheri, S. (2021). Fine crackles on chest auscultation in the early diagnosis of idiopathic pulmonary fibrosis: a prospective cohort study. BMJ open respiratory research, 8(1), e000815. https://doi.org/10.1136/bmjresp-2020-000815
  7. Sgalla, G., Walsh, S. L. F., Sverzellati, N., Fletcher, S., Cerri, S., Dimitrov, B., Nikolic, D., Barney, A., Pancaldi, F., Larcher, L., Luppi, F., Jones, M. G., Davies, D., & Richeldi, L. (2018). “Velcro-type” crackles predict specific radiologic features of fibrotic interstitial lung disease. BMC pulmonary medicine, 18(1), 103. https://doi.org/10.1186/s12890-018-0670-0